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Abstract
Background: It is not known if there is a difference in the immune response to syphilis between HIV-infected and
uninfected individuals.
Methods: We prospectively recruited all patients with a new diagnosis of syphilis and tested their plasma for IFNα,
IFNγ, IL-1β, IL-12p40, IL-12p70, IP-10, MCP-1, MIP-1α, MIP-1β, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10 and IL-17A at baseline
pre-treatment and 6 months following therapy.
Results: A total of 79 HIV-infected [44 primary/secondary syphilis (PSS) and 35 latent syphilis (LS)] and 12 HIV-uninfected
(10 PSS and 2 LS) cases of syphilis and 30 HIV-infected controls were included in the study. At the baseline visit,
compared to the control group, concentrations of IL-10 were significantly elevated in the HIV-infected and
uninfected groups. The level of IL-10 was significantly higher in the HIV-infected compared to the HIV-uninfected PSS
group (25.3 pg/mL (IQR, 4.56–41.76) vs 2.73 pg/mL (IQR, 1.55–9.02), P = 0.0192). In the HIV-infected PSS group (but not
the HIV-infected LS or HIV-uninfected PSS groups) the IP-10, MIP-1b, IL-6 and IL-8 were raised compared to the
controls. IL-10 levels decreased but did not return to control baseline values by 6 months in HIV infected PSS and LS
and HIV uninfected PSS.
Conclusion: PSS and LS in HIV-infected individuals is characterized by an increase in inflammatory and anti-inflammatory
cytokines such as IL-10. The increase of IL-10 is greater in HIV-infected than uninfected individuals. Further work is
required to ascertain if this is part of an immunological profile that correlates with adverse outcomes such as serofast
syphilis and neurosyphilis, in HIV-infected individuals.
Keywords: Syphilis, HIV, Immunology, IL-10, Treponema pallidum
Background
Syphilis is a multi-stage disease caused by infection with
Treponema pallidum subsp. pallidum (T. pallidum). A
number of studies have found the natural course of
syphilis to be altered in HIV-infected patients. The alter-
ations include a higher rate of asymptomatic primary
disease [1], more aggressive primary or secondary stage
disease [2, 3] and a higher proportion (up to a quarter)
presenting with mixed primary and secondary stage
disease at the time of diagnosis [3, 4]. There is also evi-
dence that neurosyphilis may occur more frequently, at
an earlier stage and progress more rapidly in the
presence of HIV infection [5–7]. Serological cure in the
cerebrospinal fluid (CSF) [8] and peripheral blood [3, 9–11]
has been shown to be slower in HIV-infected individuals.
Unusual serological diagnostic test results such as false
negative treponemal and non-treponemal tests in syphilis
may also be more common among persons with HIV
infection [12, 13].
These findings generate the hypothesis that the im-
mune responses to syphilis differ by HIV-infection
status. Most previous studies have characterized the
immune response to syphilis in animal models or in
HIV-uninfected individuals [14–20]. The only study that
we are aware of that has included an HIV-infected popu-
lation was weakened by its retrospective study design,
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small sample size, small number of cytokines evaluated
and lack of HIV-uninfected and healthy HIV-infected
control groups [21].
Establishing if there is a differential immune response
to T. pallidum infection by HIV status, and more fully
characterizing what this response is in HIV-infected
individuals, is important for a number of reasons. Firstly,
in countries where the incidence of syphilis is increasing,
a large proportion of syphilis infections are occurring in
HIV-infected persons [22–24]. Typically, an increasing
proportion of cases occur in individuals with repeat
syphilis [22, 25]. This repeat syphilis is often asymptom-
atic and diagnosed purely on the basis of increased titres
of non-treponemal tests [22, 26]. Since a wide array of
other factors can cause changes in these titres, a propor-
tion of these diagnoses of repeat syphilis may be false
positives [22, 25]. If a sufficiently distinctive immuno-
logical profile of initial and repeat syphilis infection
could be established, then this could be used in verifying
the diagnosis of syphilis in these reinfection cases. Given
the fact that in some populations a majority of syphilis
reinfections are in HIV-infected individuals, an import-
ant first step in this process is determining what the
immune response to syphilis is in HIV-infected versus-
uninfected individuals [22]. Secondly, if immune response
to syphilis was found to be subverted in HIV then this
would pave the way for studies to investigate if this was
causally linked to certain poor outcomes in syphilis, such
as early neurosyphilis [7].
Methods
The Institutional Review Board of the Institute of
Tropical Medicine (ITM) and the Ethics Committee of
the University Hospital Antwerp approved this sub-
study (13/44/426). Between May 2014 and June 2015,
participants were recruited in the main study “Trepo-
nema pallidum-specific Proteomic Changes in Patients
With Incident Syphilis Infection (SeTPAT)” study (Clini-
calTrials.gov Registration Number: NCT02059525) con-
ducted at the ITM in Antwerp, Belgium. All patients
attending the ITM, Antwerp’s STI or HIV clinics, over
the age of 17 years in whom a new diagnosis of syphilis
was made and had not received antibiotics in the
preceding 30 days were prospectively recruited into the
study (See Additional file 1: Figure S1 for Participant
Inclusion Process). The diagnosis and staging of syphilis
was according to the Centers for Disease Control and
Prevention classification [27]. All patients were assessed
according to a standardized protocol that collected
detailed information about sexual behavior, clinical fea-
tures and laboratory tests including Rapid Plasma Reagin
test (RPR), Treponema pallidum Particle Agglutination
(TPPA) and C-Reactive Protein (CRP). The RPR titre
was tested using Macro-Vue RPR card tests (Becton
Dickinson, Sparks, MD, USA) and the TPPA with
SERODIA-TPPA (Fujirebio Inc., Tokyo, Japan), according
to the manufacturer’s instructions. HIV viral loads below
the limit of detection (20 copies/mL) were given the value
of 10 copies/mL. The presence of concomitant sexually
transmitted infections (STIs) (gonorrhea and chlamydia)
was assessed via an Abbott RealTime CT/NG assay
(Abbott Molecular, Des Plaines, IL, USA).
Patients were followed up at 3, 6, 9 and 12 months.
Patient clinical and laboratory characteristics were re-
corded at each consultation. In addition, 30 HIV positive
controls attending the same HIV clinic and at the same
time as the cases were recruited. Blood was drawn into
EDTA-coated tubes (Sarstedt Monovette, Nümbrecht,
Germany) and separated by centrifugation at 2000 g for
10 min at ambient temperature. Within 3 h of collection,
plasma was frozen and stored at −80 °C until testing.
To avoid collection bias all samples were processed in the
same fashion according to the study standard operating
procedures.
Chemokines (Monocyte Chemoattractant Protein [MCP]-1,
Macrophage Inflammatory Protein [MIP]-1α, MIP-1β, IFNγ-
Inducible Protein [IP]-10, Interleukin [IL]-8) and cytokines
(Interferon [IFN]α, IFNγ, IL-1 β, IL-12p40, IL-12p70,
IL-4, IL-5, IL-6, IL-7, IL-10 and IL-17A) from the
baseline and 6 month post-treatment time-points, and
from an additional two individuals 3 and 12 months
before their syphilis diagnosis, were measured in a
single experiment using a magnetic bead Milliplex™
Human Cytokine kit (Millipore, MA, USA) on a Bio-
Plex™ Suspension Array Reader (Bio-Rad Laboratories
Inc®, CA, USA) in accordance with the manufacturer’s
instructions. Standard curves were constructed using
duplicate measurements of kit standards. Samples
below the limit of quantification were assigned the
value of half the lowest limit detected for each cytokine
(see Additional file 1: Table S1).
Statistical analyses
Values are summarized as medians and interquartile
ranges (IQR). In keeping with previous studies, we found
that the immunological profiles of syphilis differed be-
tween primary and secondary stage syphilis combined
group (PSS) and early and late latent stage syphilis
combined group (LS) [20, 21]. All results are therefore
presented stratified by PSS versus LS. There were only
two HIV-uninfected patients diagnosed with LS and no
comparisons are therefore made with this group. Com-
parison of the inter-individual data between the PSS,
and LS groups was performed using the Mann-Whitney
U-test. Wilcoxon signed rank test was used to evaluate
intra-individual changes from baseline to six-month
visit. Correlations were assessed via Spearman’s rank
correlation coefficient. Due to the small sample size and
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the fact that this is the first study of its kind, the
study was conceived as being exploratory rather than
hypothesis testing. This, combined with the fact that
the cyto- and chemokines under investigation are
known to be inter-dependent, led us to not utilize
Bonferroni corrections [28–30]. All analyses were per-
formed in Stata 13 (StataCorp LP, College Station,
TX, USA). A P-value of less than 0.05 was considered
statistically significant.
Results
A total of 79 HIV-infected [44 PSS and 35 LS] and 12
HIV-uninfected (10 PSS and 2 LS) cases of syphilis and
30 HIV-infected controls were included in the study (see
Additional file 1: Figure S1 for inclusion process). At
baseline, the age, number of sex partners in the prior
12 months, proportion with a previous episode of
treated syphilis, prevalence of other STIs diagnosed at
baseline, RPR titre and syphilis treatment received did
not differ significantly between HIV-infected and unin-
fected PSS groups (Table 1). Likewise, except for a
higher HIV viral load in the controls than the PSS and
LS groups, there was no significant difference in the age,
CD4 T cell count, percent on antiretroviral therapy
(ART) or HIV viral load between the controls and HIV-
infected syphilis patients. All patients were treated with
intramuscular benzathine penicillin G, except for two
patients who were treated with oral doxycycline. Only
one participant was a woman. She was HIV negative and
presented with secondary syphilis. All the men with
syphilis, excluding two individuals, reported being men
who have sex with men (MSM).
Baseline immunological profile
At the baseline visit, compared to the control group,
concentrations of the anti-inflammatory cytokine IL-10
were significantly elevated in both the HIV-infected and
uninfected groups (Fig. 1; Table 2). The level of IL-10 was
strikingly higher in the HIV-infected PSS compared to the
HIV-uninfected PSS group (25.3 pg/mL (IQR, 4.56–41.76)
versus 2.73 pg/mL (IQR, 1.55–9.02), P = 0.0192). In
the HIV-infected PSS group (but not the HIV-
infected LS or HIV-uninfected PSS groups) the che-
mokines IP-10, MIP-1β, IL-8 and the pro-inflammatory
cytokine IL-6 were raised significantly compared to the
controls. Of these only the MIP-1β level was significantly
higher in the HIV-infected PSS than uninfected PSS group
(P = 0.0205).
Six-month immunological profile
In seven out of 91 individuals with syphilis we had
baseline but no 6-month samples. At 6 months post
syphilis treatment the levels of IL-10 had declined in
all groups, and most strikingly in the HIV-infected
PSS group. IL-10 remained significantly elevated com-
pared to the control group (P < 0.0001 to 0.0018).
There was no longer a difference in IL-10 levels
between the HIV-infected and uninfected PSS groups.
Table 1 Baseline characteristics
Controls Primary/Secondary syphilis Latent Syphilis
(n = 30) HIV+ (n = 44)# HIV-(n = 10)# HIV+ vs. HIV-, P$ HIV+(n = 35)#
Men 30 (100%) 44 (100%) 9 (90%)* 0.0359 35 (100%)
Age (years) 37 (32–45) 39.5 (30.5–50.0) 34 (30–43) 0.4689 40 (35–46)
MSM 24 (80%) 44 (100%) 9 (90%) 0.0359 34 (94.7.1%)
CD4 T cell count (cells per μL) 577 (392–684) 649 (452–838) 800 (800–800) 0.4537 590 (433–691)
HIV Viral Load (copies per mL) 34 (10–814) 10 (10–53)* NA NA 10 (10–25)**
On Antiretroviral Therapy 24 (80%) 39 (88.6%) NA NA 31 (88.6%)
RPR titre 0 (0–0) 1/64 (1/32–1/128) 1/64 (1/16–1/128) 0.5556 1/64 (1/16–1/128)
Treatment 1.0
Benzathine-penicillin G NA 44 (100%) 10 (100%) 33 (94.3%)
Doxycycline NA 0 0 2 (5.7%)
Previous treated syphilis NA 27 (61.3%) 3 (30%) 0.0743 24 (68.6%)
Other STIs presenta 0 (30) 1 (2.3%) 0 (0%) 0.63 2 (5.7%)
No. of sex partners prior 12 months 1.5 (1–6) 8.5 (2–26)** 6.5 (2–8)* 0.5174 7 (1–12)*
Data are n (%), median (IQR), unless otherwise stated. NA - Not Applicable
*P < 0.05, ** P < 0.005
#P-value is for comparison with controls at baseline (Mann-Whitney U-test, excluding ‘Men’, ‘MSM’, ‘On Antiretroviral Therapy’ and ‘Other STIs’ where Fisher’s exact
test used)
$P-value is for comparison between HIV-infected and uninfected groups (Mann-Whitney U-test, except ‘Men’, ‘MSM’, ‘Treatment’, ‘Previous treated syphilis’ and
‘Other STIs’ where Fisher’s exact test used)
aPresence of N. gonorrhoeae or C. trachomatis in urethra, rectum or oropharynx
MSM: men who have sex with men
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Another interesting observation was that IFNα levels
declined in all groups and at 6 months attained sig-
nificantly lower levels than the HIV-infected control
group (P = 0.0007 to 0.0104).
Intra-individual change in IL-10 & IFNα concentrations
IL-10
There was a significant decline in IL-10 from baseline to
6 month visit in the HIV-infected PSS group (P < 0.0001),
Fig. 1 Plasma cytokine and chemokine concentrations in HIV-infected and uninfected patients with syphilis by syphilis stage at baseline and
6 month visit. Cytokine levels in each group (pg/ml, Y axis log scale) are shown as median and interquartile range (box), with 10th and 90th percentiles
(whiskers). Letters (a) and (b) above the box-plot indicate statistically significant differences (P < 0.05) as compared with the HIV-infected controls and
the comparison between HIV-infected and uninfected PSS groups, respectively. Abbreviations. PSS HIV+: Primary Secondary Syphilis HIV-infected, LS
HIV+: Latent Syphilis HIV-infected, PSS HIV-: Primary Secondary Syphilis HIV-uninfected
Kenyon et al. BMC Infectious Diseases  (2017) 17:111 Page 4 of 9
Table 2 Plasma cytokine and chemokine concentrations in HIV-infected and uninfected patients with syphilis by syphilis stage (pg/ml)
HIV-infected Controls HIV-infected HIV-uninfected
Primary/Secondary Syphilis# Latent Syphilis# Primary/Secondary Syphilis# PSS HIV+ vs. -, P$
Baseline
N 30 44 35 10
Pro-inflammatory
IFNα 9.88 (1.6–16.43) 7.45 (0.8–31.35) 7.45 (0.8–20.42) 4.12 (0.8–24.73) 0.5202
IL1β 1.57 (1.57–1.57) 1.57 (1.57–1.57) 1.57 (1.57–1.57) 1.57 (1.57–1.57) 0.4883
IL-6 1.26 (1.26–1.26) 1.26 (1.26–1.26)* 1.26 (1.26–1.26) 1.26 (1.26–1.26) 0.722
IL-17A 1.52 (1.52–1.52) 1.52 (1.52–1.52) 1.52 (1.52–1.52) 1.52 (1.52–1.52) 0.8358
Th1
IFNγ 2.18 (1.54–4.59) 3.52 (1.54–5.45) 1.79 (1.54–4.59) 4.01 (1.54–16.66) 0.5991
IL-7 1.11 (1.11–1.11) 1.11 (1.11–1.36) 1.11 (1.11–1.11) 1.11 (1.11–1.11) 0.357
IL-12p40 1.02 (1.02–1.02) 1.02 (1.02–1.02) 1.02 (1.02–1.02) 1.02 (1.02–1.02) 0.4056
IL-12p70 1.61 (1.61–1.61) 1.61 (1.61–1.67) 1.61 (1.61–1.61) 1.61 (1.61–4.08) 0.6264
Chemokines
IL-8 1.6 (1.6–5.06) 4.51 (2.41–7.43)** 1.6 (1.6–3.15) 1.6 (1.6–5.13) 0.0723
IP-10 589.4 (319.38–917.05) 1016.1 (649.64–1451.32)** 696.89 (455.35–1101.67) 696.52 (426.27–1040.07) 0.1561
MCP-1 258.42 (179.09–307.75) 260.1 (216.95–307.35) 242.05 (180.35–303.1) 247.64 (205.76–287.32) 0.4321
MIP-1α 1.63 (1.63–3.65) 3.09 (1.63–8.3) 1.63 (1.63–1.63) 1.63 (1.63–1.63) 0.1247
MIP-1β 14.54 (0.99–22.23) 28.59 (16.06–42.51)** 15.2 (4.92–22.23) 8.46 (4.92–23.05) 0.0205
Th2
IL-4 1.58 (1.58–1.58) 1.58 (1.58–1.58) 1.58 (1.58–1.58) 1.58 (1.58–1.58) 0.4883
IL-5 1.58 (1.58–1.58) 1.58 (1.58–1.58) 1.58 (1.58–1.58) 1.58 (1.58–1.58) 0.3324
Anti-inflammatory
IL-10 1.55 (1.55–1.55) 25.3 (4.56–41.76)*** 2.46 (1.55–4.62)* 2.73 (1.55–9.02)* 0.0029
6 month
N 41 34 10
Pro-inflammatory
IFNα 0.8 (0.8–9.27)**# 0.8 (0.8–7.8)**# 0.8 (0.8–0.8)*# 0.3282
IL-1β 1.57 (1.57–1.57) 1.57 (1.57–1.57) 1.57 (1.57–1.57) 0.1798
IL-6 1.26 (1.26–1.26) 1.26 (1.26–1.26) 1.26 (1.26–1.26) 0.7379
IL-17A 1.52 (1.52–1.52) 1.52 (1.52–1.52) 1.52 (1.52–1.52) 0.7379
Th1
IFNγ 1.54 (1.54–5.09) 1.62 (1.54–4.88) 5.17 (1.54–13.89) 0.0978
IL-7 1.11 (1.11–1.11) 1.11 (1.11–1.11) 1.11 (1.11–1.11) 0.6486
IL-12p40 1.02 (1.02–1.02) 1.02 (1.02–1.02) 1.02 (1.02–1.02) 0.2068
IL-12p70 1.61 (1.61–1.61) 1.61 (1.61–1.86) 1.61 (1.61–1.61) 0.7639
Chemokines
IL-8 1.87 (1.6–4.02) 1.6 (1.6–1.7) 1.66 (1.6–3.75) 0.4406
IP-10 564.56 (392.18–740.03) 592.04 (447.8–831.96) 447 (309–593) 0.2134
MCP-1 270.25 (225.5–330.3) 261.32 (241.06–312.26) 269 (219–297) 0.8287
MIP-1α 1.63 (1.63–1.63) 1.63 (1.63–1.63) 1.63 (1.63–1.63) 0.6726
MIP-1β 7.4 (0.99–20.28) 9.17 (1.99–14) 2.39 (0.99–12.05) 0.249
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and a non-significant decline in the HIV-infected LS
group and the HIV-uninfected PSS group (P = 0.4803 and
0.4838, respectively; Table 2 & Fig. 2).
IFNα
Over the same time period, there was a significant
decline in IFNα in the HIV-infected LS group (P <
0.0412), but this change was borderline significant in
the HIV-infected PSS group (P = 0.0568) and not sig-
nificant in the HIV-uninfected PSS group (P = 0.3173;
Table 2 & Fig. 1).
In the two individuals for which we were able to test
their cytokine profile before, during and after PSS infec-
tion there was an increase in IL-10 at the time of infec-
tion and a return to pre-syphilis values after 6 months.
These individuals were originally included as controls
and then during the course of the study developed a
syphilis infection. Conversely, IFNα levels in these two
decreased at the time of secondary stage syphilis diagno-
sis and continued to drop until the 6-month visit.
IL-10 Correlation analyses
At the baseline visit there were differences between the
HIV-infected and uninfected groups in the immuno-
logical markers that were correlated with IL-10 level. In
the HIV-infected PSS group, IL-10 was significantly
positively correlated with IL-12p40, IL-12p70, MIP-1α,
MIP-1β, IL-5, IL-6, IL-7 and IL-8 (r = 0.36, 0.67, 0.59,
0.61, 0.75, 0.79, 0.83, 0.53, respectively; Additional file 1:
Table S2a). In the HIV-uninfected group there were no
significant correlations with IL-10 (Additional file 1:
Table S2b). There were however only 10 individuals in
this group.
None of the cohort was diagnosed with treatment fail-
ure or neurosyphilis subsequent to the baseline visit and
we were thus unable to assess if any particular immuno-
logical profile was predictive of these adverse outcomes.
In sensitivity analyses we excluded the one woman
from the analyses and repeated the analyses with the
PSS group split into primary syphilis (PS) and secondary
syphilis (SS) and the LS group split into early latent and
late latent syphilis. We also repeated the analyses with
the HIV-infected group limited to those taking ART.
These made little difference to the results (results not
shown). Scatterplots revealed that the difference in IL-6
between controls and the HIV-infected PSS group was
largely driven by two outlier values. Repeating the
comparison between these two groups excluding these
two outliers, there was no longer a statistically higher
IL-6 level in the HIV-infected group.
Discussion
The most prominent difference in the plasma immuno-
logical response to PSS between the HIV-infected and
uninfected was a ten-fold higher IL-10 response in the
HIV positive group. Although this is a new finding, it is
not incommensurate with findings from other studies.
The study by Knudsen et al. [21] found similarly high
levels of IL-10 in HIV-infected PSS (46.7 pg/mL; IQR
28.4–78.9) and LS (13.4 pg/mL; IQR 6.5–31.1). Many
studies in HIV-uninfected populations have not assessed
IL-10 levels [15, 17, 31]. Those that have, found either
Table 2 Plasma cytokine and chemokine concentrations in HIV-infected and uninfected patients with syphilis by syphilis stage (pg/ml)
(Continued)
Th2
IL-4 1.58 (1.58–1.58) 1.58 (1.58–1.58) 1.58 (1.58–1.58) 0.1798
IL-5 1.58 (1.58–1.58) 1.58 (1.58–1.58) 1.58 (1.58–1.58) 0.3621
Anti-inflammatory
IL-10 1.83 (1.83–4.09)*** 2.11 (1.83–3.37)*** 2.26 (1.83–4.46)** 0.6296
All values are median and interquartile range. Data are n (%), median (IQR), unless otherwise stated
#P-value is for comparison with controls at baseline (Mann-Whitney U-test)
$P-value is for comparison between HIV-infected and uninfected groups with Primary/Secondary syphilis (Mann-Whitney U-test)
*P < 0.05, ** P < 0.005, ***P < 0.0005
PSS - Primary/Secondary Syphilis
Fig. 2 IL-10 response to primary and secondary syphilis infection in
HIV-infected (solid lines) and uninfected individuals (dashed lines) at the
time of infection (baseline visit) and at 6 months follow up (log scale)
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IL-10 to be not raised [14, 19] or marginally raised [16,
20] compared to HIV-uninfected controls. These studies
used differing methodologies and as a result IL-10 values
cannot be meaningfully compared between studies. Our
study builds on these results by for the first time
comparing immunological profiles in HIV-infected and
uninfected groups.
How should we interpret the higher IL-10 levels in the
HIV-infected individuals and in the PSS group in particular?
The initial immune response to T. pallidum involves a
robust cell mediated response characterized by a Th1
predominance that results in the clearance of the vast
majority of treponemes at the lesion of the primary stage
[15, 32]. We mainly found increased levels of IL-10 and
chemokines in the PSS group. The positive correlations
we found between IL-10 and IL-12p40, IL-12p70, MIP-
1α, MIP-1β, IL-5, IL-6, IL-7 and IL-8 in the HIV-
infected PSS group could be interpreted as evidence that
the increased IL-10 is acting as a feedback response
to limit inflammation. We did not see any particular
increase of Th1 cytokines as reported by two other
studies [15, 29].
An alternative/complementary explanation is that T.
pallidum is playing a role in the IL-10 elevation. In a
proportion of cases, T. pallidum is able to evade the im-
mune system and set up secondary and chronic latent
stages of infection [14]. Poor antigenicity and antigenic
variation have been shown to play an important role in
this regard [33–35]. A further mechanism is that an en-
hanced regulatory T-cell (Treg) response in early syphilis
may down-regulate the immune response to T. pallidum
and thereby facilitate its survival [17, 31, 36]. IL-10 plays
an important role in the establishment of the Treg anti-
inflammatory effect that is important in preventing
overwhelming inflammatory responses [37]. These im-
munosuppressive properties of IL-10 have also been
shown to be harnessed by a number of pathogens to
facilitate persistent infection: Borrelia burgdorferi [38],
Plasmodium spp. [39], Leishmania spp. [40] and Mycobac-
terium tuberculosis [37].
Babolin et al. provided experimental evidence that the
T. pallidum protein, TpF1 bacterioferrin, is able to in-
duce a Treg response in patients with secondary syphilis
via the induction of IL-10 and TGF-β [41]. Podwinska
and colleagues investigated the ability of lymphocytes to
produce cytokines from patients at different stages of
syphilis in response to stimulation with T. pallidum anti-
gen [20]. They noted a stepwise increase in IL-10 pro-
duction from primary syphilis to secondary and latent
syphilis that correlated inversely with the ability to
produce IL-2 (a Th1 cytokine). In a study of 531 syphilis
patients with and without neurosyphilis, Li and colleagues
found evidence that Tregs play a role in treponemal
persistence and the genesis of neurosyphilis in HIV-
uninfected individuals [17]. They demonstrated that
secondary and serofast syphilis patients had increased
Treg percentages in their peripheral blood compared with
healthy controls. Patients with neurosyphilis had a higher
frequency of Tregs in peripheral blood compared to non-
neurosyphilis patients. In a similar vein, Pastuszczak et al.,
found that IL-10 was considerably higher in the CSF of
patients with neurosyphilis than syphilis patients without
neurological involvement [19]. These findings are also
consistent with the clinical study by Knudsen et al., which
was able to demonstrate with a high degree of probability
that T. pallidum infection was the cause of the IL-10
elevation [21].
HIV-infection is characterized by a Th1 to Th2 cyto-
kine shift during the course of the infection [42] which
includes an enhanced potential for robust IL-10 and
associated Treg response [43–45]. If HIV infection leads
to a more pronounced Treg response to infection with
T. pallidum, then this could explain a number of the
atypical features of syphilis in HIV-infected individuals
mentioned in the introduction. The recently established
correlation between Treg activity and risk of serofast
syphilis and neurosyphilis [17] in HIV-uninfected in-
dividuals suggests the need for more investigations
along these lines in HIV co-infected patients. The dis-
covery of an immunological profile strongly associated
with asymptomatic neurosyphilis would be of consid-
erable clinical utility.
Limitations in our study include that we only mea-
sured systemic cytokine responses and not cytokine
secretions in response to antigenic (T. pallidum antigen)
stimulation. The detection of cytokines in plasma
samples has several limitations. First of all, cytokine
responses are mainly local and short-ranged. We only
detect cytokine overflow in the systemic circulation.
Secondly, we have no data about the cell types that se-
creted these and conclusions are thus largely speculative.
Thirdly, cytokine measurements in plasma are critically
dependent on proper sample collection, storage and the
technology used to detect them. We ensured that the
cytokine detection was done under optimal circum-
stances such as prompt sample processing in order to
minimize undesirable test variation due to suboptimal
storage and test conditions.
In addition, the small sample size and the fact that al-
most the entire cohort were MSM, with high-risk behav-
ior, thereby reducing the generalizability of the results.
We did not resample the control group at 6-months and
thus did not have a control group for the 6-month sam-
ples. The fact that those diagnosed with syphilis reported
a higher number of sexual partners than the controls
raises the possibility that they were co-infected with
other undiagnosed STIs. Given the fact that there was
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no statistically significant difference in the number of
partners, or the diagnosis of STIs between the PSS HIV-
infected and uninfected subjects, this explanation is
unlikely to explain the immunological differences found
between these two groups. Our HIV-infected patients
included both those receiving and not receiving ART,
which may have influenced our results, however, we
consider this as unlikely as repeating the analyses re-
stricted to those on ART did not substantively change
the results. We did not assess patients’ genotypes for
IL-10 and other cytokines. A number of IL-10 single
nucleotide polymorphisms have been found to be associ-
ated with both IL-10 inducibility [19] and susceptibility
to infectious diseases such as tuberculosis [46] and
neurosyphilis [19]. For a number of the chemo- and
cytokines, only a small proportion of samples had levels
above the level of detection (Additional file 1: Table S1),
particularly in the cases of IL1b, IL-6, IL-17A, IL-7, IL-
12p40, IL-4 and IL-5. A number of these low abundance
chemo- and cytokines had low correlations between
technical duplicates (Additional file 1: Table S1). The
results for these chemo- and cytokines need to be
interpreted with considerable caution. Furthermore, we
did not correct for multiple comparisons which may
have led to type I errors [28]. The strengths of the study
include its setting within a prospective observational
cohort study wherein the patients had their behavioral,
clinical and laboratory characteristics collected in a
detailed and standardized fashion.
Conclusion
In conclusion, we demonstrate that PSS and LS in
HIV-infected individuals is characterized by not only an
increase in inflammatory- but also the anti-inflammatory-
cytokine, IL-10. The increase of IL-10 is greater in HIV-
infected than uninfected individuals and declines but does
not return to baseline levels by 6-month post- infection.
Further work is required to ascertain if there is an immuno-
logical profile that specifically correlates with adverse
outcomes such as treatment failure, serofast- and neuro-
syphilis in HIV-co-infected individuals.
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